Depletion and replacement of Tet2-mutant HSPC after CD45-ADC conditioning. (A) Schematic depiction of the experimental outline for modeling Tet2 KO–driven clonal hematopoiesis and atherosclerosis. (B) Peripheral blood WT or Tet2 KO chimerism (CFP) in atherosclerotic Ldlr KO recipient mice, week 0 to 16 after bone marrow transplantation. (C) Representative FACS plots of CFP chimerism in the peripheral blood, 16 weeks after transplantation into Ldlr KO mice. (D) Bar graphs showing FACS analysis of CD45.1 chimerism, 6 weeks after CD45-ADC treatment, and CD45.1⁺ HSCT in atherosclerotic Ldlr KO mice with either WT or Tet2 KO bone marrow. (E) FACS assessment of CD45.1 chimerism, 6 weeks after CD45-ADC treatment, and CD45.1⁺ HSCT in atherosclerotic Ldlr KO mice with either WT or Tet2 KO bone marrow, displayed as bar graphs. (F) Number of LT-HSCs per femur in atherosclerotic Ldlr KO mice with either WT or Tet2 KO bone marrow, as determined by flow cytometric analysis.